incurable/non-metastatic hepatocellular carcinoma
Conditions
Interventions
Case group:None
Doctor team:None
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Chart review:(1)Patient was >=18 years on the index date. (2)Patient was newly confirmed diagnosis by imaging, histology, or cytology incurable/non-metastatic hepatocellular carcinoma oBCLC A (incurable), B, C(non-metastatic) or CNLC Ia ~ IIb (incurable); oif no staging conclusion, follow the definition: BCLC stage A is defined as solitary HCC irrespective of size or as a multifocal HCC up to 3 nodules (none of them >3 cm), without macrovascular invasion, extrahepatic spread or cancer-related symptoms (PS 0) . BLCLC stage B is defined as patients with multifocal HCC (exceeding BCLC-A criteria) with preserved liver function, no cancer related symptoms (PS 0) and no vascular invasion or extrahepatic spread. Non-metastatic BCLC stage C is defined as HCC localized to the liver without portal vein thrombosis, basically PS 1-2. CNLC stage Ia is defined as PS 0 to 2, Child-Pugh grade A/B, a single tumor, diameter 5 cm, or 2 to 3 tumors, maximum diameter 3cm, no imaging visible vascular tumor thrombus and extrahepatic metastasis (4). CNLC stage IIb is defined as PS 0~2, Child-Pugh grade A/B, >=4 tumors, any tumor diameter, no imaging visible vascular tumor thrombus and extrahepatic metastasis. Incurable HCC was defined as follow: Recorded as "incurable" in site database. OR Received incurable treatment, excluding treatments like surgery, ablation, transplant. OR PI defined as HCC that did not meet the principles of completeness and safety of curable treatment. (3)Received the first anti-tumor treatment for incurable/non-metastatic HCC in 2024. (4)At least once follow-up since the index date. 2.Doctor survey: (1)Work in tertiary Class A hospital. (2)>=3 years of experience in managing incurable/non-metastatic HCC patients with the title of vice chief doctor, chief doctor or attending doctor. (3)Doctor with >=15 incurable/non-metastatic HCC patients in the past 1 year of practice. (4)Have prescribed the model of locoregional plus ICI and TKI in the past 1 year. (5)All eligible doctors need to provide informed consent.
Exclusion criteria
Exclusion criteria: 1.Chart review: (1)Pathological diagnosis of mixed liver cancer, fibrolamellar cell carcinoma, or other non-hepatocellular malignant tumor components. (2)Patient prior or concurrent with multiple primary cancers. (3)Baseline examination (after diagnosis, prior to initial treatment) indicates tumor is curable or has progressed to metastatic stage. 2.Docter survey:None.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Characteristics and Treatment Decision Factors;Initial Treatment Patterns; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival with TACE-Only Therapy; | — |
Countries
China
Contacts
Public ContactTeng Gaojun
Zhejiang Cancer Hospital
Outcome results
None listed